Histopathology最新文献

英文中文

Time requirements for diagnosing mesothelioma in situ 诊断原位间皮瘤的时间要求

IF 3.9 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-16 DOI: 10.1111/his.15322

Andrew Churg

引用次数: 0

Cellular congenital mesoblastic nephroma with focal anaplasia, report of a case 细胞性先天中胚层肾瘤伴局灶性无细胞增生，一例报告

IF 3.9 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-13 DOI: 10.1111/his.15286

Ashlie Rubrecht, Nilay Shah, Jennifer H. Aldrink, Kathleen M. Schieffer, Laura E Biederman

引用次数: 0

Recommendation on the minimum time for follow-up in diagnosing mesothelioma in situ 关于诊断原位间皮瘤的最短随访时间的建议

IF 3.9 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-13 DOI: 10.1111/his.15320

Kazuki Nabeshima

引用次数: 0

Spectra of well‐differentiated neuroendocrine lesions in the extrahepatic biliary system: a case series 肝外胆道系统中分化良好的神经内分泌病变的光谱：一个病例系列

IF 6.4 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-13 DOI: 10.1111/his.15316

Yongjun Liu, Ashwini K Esnakula, Shilpa Jain, Jingmei Lin, Nicole Panarelli, Sergey Pyatibrat, Dipti M Karamchandani

AimsNeuroendocrine tumours (NETs) occurring in the extrahepatic biliary system are exceedingly rare. While NETs typically manifest as mass lesions, the occurrence of microscopic neuroendocrine cell proliferation without a distinct mass remains undocumented at this location. This study aims to characterise the clinicopathological features of a series of well‐differentiated neuroendocrine lesions involving the extrahepatic biliary tree, including mass forming NETs and microscopic non‐mass‐forming neuroendocrine cell proliferation, designated neuroendocrine cell micronests (NCMs).Methods and resultsSurgical resections of NETs/NCMs involving the extrahepatic bile ducts and gallbladder were identified from electronic pathology databases among seven institutions spanning from January 2011 to September 2023. Clinical and histological findings were recorded. Ten patients (four female, six male: age range = 34–75 years) were included in the study. Histopathological examination revealed visible mass‐forming lesions in four cases (1.6–14.0 cm in size), identified in the gallbladder (n = two) or extrahepatic bile duct (n = two), all diagnosed as well‐differentiated NETs. The remaining six cases revealed incidental non‐mass‐forming NCMs in either the cystic duct (n = two), common bile duct (n = three) or gallbladder (n = one), ranging from < 0.1 to 0.4 cm; four were associated with biliary lithiasis. No evidence of metastasis or recurrence was seen in the follow‐up period (range = 0.1–11.2 years).ConclusionsThis study highlights the spectrum of extrahepatic biliary well‐differentiated neuroendocrine lesions, ranging from incidental microscopic NCMs to grossly apparent mass‐forming NETs, potentially requiring different clinical management. Noteworthy is the frequent association of incidental microscopic neuroendocrine cell proliferations with biliary lithiasis, indicating a potential neuroendocrine metaplastic pathogenesis that merits further exploration.

目的发生在肝外胆道系统的神经内分泌肿瘤（NET）极为罕见。虽然NET通常表现为肿块性病变，但在该部位发生的无明显肿块的微小神经内分泌细胞增生仍未见记载。本研究旨在描述一系列累及肝外胆管的分化良好的神经内分泌病变的临床病理特征，包括肿块型NET和显微镜下非肿块型神经内分泌细胞增生，即神经内分泌细胞微巢（NCMs）。方法和结果从2011年1月至2023年9月期间的七个机构的电子病理数据库中确定了累及肝外胆管和胆囊的NET/NCMs手术切除病例。记录了临床和组织学检查结果。研究共纳入了十名患者（四名女性，六名男性：年龄范围 = 34-75 岁）。组织病理学检查显示，四例患者（1.6-14.0 厘米大小）有明显的肿块病变，分别位于胆囊（2 例）或肝外胆管（2 例），均被诊断为分化良好的 NET。其余六例病例在胆囊管（两例）、胆总管（三例）或胆囊（一例）中偶然发现非肿块型NCM，大小从0.1厘米到0.4厘米不等；其中四例伴有胆道结石。结论本研究强调了肝外胆道分化良好的神经内分泌病变的范围，从偶然的显微镜下NCM到大体明显的肿块型NET，可能需要不同的临床治疗。值得注意的是，偶然出现的微小神经内分泌细胞增生与胆道结石频繁相关，这表明潜在的神经内分泌变态反应发病机制值得进一步探讨。

{"title":"Spectra of well‐differentiated neuroendocrine lesions in the extrahepatic biliary system: a case series","authors":"Yongjun Liu, Ashwini K Esnakula, Shilpa Jain, Jingmei Lin, Nicole Panarelli, Sergey Pyatibrat, Dipti M Karamchandani","doi":"10.1111/his.15316","DOIUrl":"https://doi.org/10.1111/his.15316","url":null,"abstract":"AimsNeuroendocrine tumours (NETs) occurring in the extrahepatic biliary system are exceedingly rare. While NETs typically manifest as mass lesions, the occurrence of microscopic neuroendocrine cell proliferation without a distinct mass remains undocumented at this location. This study aims to characterise the clinicopathological features of a series of well‐differentiated neuroendocrine lesions involving the extrahepatic biliary tree, including mass forming NETs and microscopic non‐mass‐forming neuroendocrine cell proliferation, designated neuroendocrine cell micronests (NCMs).Methods and resultsSurgical resections of NETs/NCMs involving the extrahepatic bile ducts and gallbladder were identified from electronic pathology databases among seven institutions spanning from January 2011 to September 2023. Clinical and histological findings were recorded. Ten patients (four female, six male: age range = 34–75 years) were included in the study. Histopathological examination revealed visible mass‐forming lesions in four cases (1.6–14.0 cm in size), identified in the gallbladder (n = two) or extrahepatic bile duct (n = two), all diagnosed as well‐differentiated NETs. The remaining six cases revealed incidental non‐mass‐forming NCMs in either the cystic duct (n = two), common bile duct (n = three) or gallbladder (n = one), ranging from < 0.1 to 0.4 cm; four were associated with biliary lithiasis. No evidence of metastasis or recurrence was seen in the follow‐up period (range = 0.1–11.2 years).ConclusionsThis study highlights the spectrum of extrahepatic biliary well‐differentiated neuroendocrine lesions, ranging from incidental microscopic NCMs to grossly apparent mass‐forming NETs, potentially requiring different clinical management. Noteworthy is the frequent association of incidental microscopic neuroendocrine cell proliferations with biliary lithiasis, indicating a potential neuroendocrine metaplastic pathogenesis that merits further exploration.","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"8 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma BRCA1-相关蛋白-1失活黑色素细胞瘤：临床病理学谱系特征和黑色素瘤中优先表达抗原的免疫组化表达模式

IF 6.4 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-13 DOI: 10.1111/his.15318

Yitong Xu, Alejandro A Gru, Thomas Brenn, Katharina Wiedemeyer

AimsBRCA1‐associaed protein‐1 (BAP1) inactivated tumours (BIMT) are rare melanocytic tumours that may be mistaken for Spitz tumours or melanoma. They occur sporadically or in association with the BAP1 tumour predisposition syndrome (BAP1–TPDS), which may be complicated by uveal or cutaneous melanoma, mesothelioma, basal cell carcinoma and renal cell carcinoma. The aim of this study was to characterise the clinicopathological features and the immunohistochemical expression pattern of preferentially expressed antigen in melanoma (PRAME) of BIMT in a large patient cohort.Methods and resultsEthical approval was obtained, haematoxylin and eosin‐stained slides were reviewed, PRAME immunohistochemistry was performed and clinical follow‐up was obtained from patient records. Sixty‐five BIMT from 38 patients (F:M = 4.4:1) were identified. BIMT were typically located on the trunk and head and neck (median size = 0.5 cm). Seven patients with BAP1–TPDS (range = 16–66 years, median = 25) had multiple BIMT (median = 5), while sporadic BIMT were solitary (median patient age = 39 years). One of seven patients with BAP1–TPDS developed additional malignancies (mesothelioma and cutaneous spindle cell melanoma) and died of complications of mesothelioma. All other patients are alive without recurrence of BIMT (median follow‐up = 42 months). BIMT presented as intradermal, nodular aggregates of epithelioid melanocytes with low mitotic activity and moderate to severe cytological atypia in 63% of cases. A background conventional naevus was present in 64%. PRAME immunohistochemistry showed negative or weakly patchy positive staining in all BIMT.ConclusionsBIMT are more common in a sporadic setting and behave indolently, despite worrying cytological atypia. PRAME immunohistochemistry is a reassuring tool in distinguishing BIMT from melanoma.

目的BRCA1-同化蛋白-1（BAP1）失活肿瘤（BIMT）是一种罕见的黑色素细胞肿瘤，可能被误认为是斯皮茨瘤或黑色素瘤。这种肿瘤可偶发，也可与 BAP1 肿瘤易感综合征（BAP1-TPDS）并发，可并发葡萄膜或皮肤黑色素瘤、间皮瘤、基底细胞癌和肾细胞癌。本研究的目的是在一个庞大的患者队列中描述 BIMT 的临床病理特征和黑色素瘤中优先表达抗原（PRAME）的免疫组化表达模式。方法和结果获得了伦理批准，审查了血栓素和伊红染色的切片，进行了 PRAME 免疫组化，并从患者记录中获得了临床随访。从38名患者（女：男=4.4:1）中鉴定出65个BIMT。BIMT 通常位于躯干和头颈部（中位尺寸 = 0.5 厘米）。7名BAP1-TPDS患者（年龄范围=16-66岁，中位数=25岁）患有多发性BIMT（中位数=5），而散发性BIMT为单发（中位数=39岁）。七名BAP1-TPDS患者中有一人罹患其他恶性肿瘤（间皮瘤和皮肤纺锤形细胞黑色素瘤），并死于间皮瘤并发症。其他患者均健在，BIMT 未复发（中位随访时间 = 42 个月）。BIMT表现为皮内上皮样黑色素细胞的结节状聚集，有丝分裂活性低，63%的病例存在中度至重度细胞学不典型性。64%的病例存在传统的痣背景。PRAME 免疫组化在所有 BIMT 中均显示阴性或弱斑片状阳性染色。PRAME 免疫组化是区分 BIMT 和黑色素瘤的可靠工具。

{"title":"BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma","authors":"Yitong Xu, Alejandro A Gru, Thomas Brenn, Katharina Wiedemeyer","doi":"10.1111/his.15318","DOIUrl":"https://doi.org/10.1111/his.15318","url":null,"abstract":"AimsBRCA1‐associaed protein‐1 (BAP1) inactivated tumours (BIMT) are rare melanocytic tumours that may be mistaken for Spitz tumours or melanoma. They occur sporadically or in association with the BAP1 tumour predisposition syndrome (BAP1–TPDS), which may be complicated by uveal or cutaneous melanoma, mesothelioma, basal cell carcinoma and renal cell carcinoma. The aim of this study was to characterise the clinicopathological features and the immunohistochemical expression pattern of preferentially expressed antigen in melanoma (PRAME) of BIMT in a large patient cohort.Methods and resultsEthical approval was obtained, haematoxylin and eosin‐stained slides were reviewed, PRAME immunohistochemistry was performed and clinical follow‐up was obtained from patient records. Sixty‐five BIMT from 38 patients (F:M = 4.4:1) were identified. BIMT were typically located on the trunk and head and neck (median size = 0.5 cm). Seven patients with BAP1–TPDS (range = 16–66 years, median = 25) had multiple BIMT (median = 5), while sporadic BIMT were solitary (median patient age = 39 years). One of seven patients with BAP1–TPDS developed additional malignancies (mesothelioma and cutaneous spindle cell melanoma) and died of complications of mesothelioma. All other patients are alive without recurrence of BIMT (median follow‐up = 42 months). BIMT presented as intradermal, nodular aggregates of epithelioid melanocytes with low mitotic activity and moderate to severe cytological atypia in 63% of cases. A background conventional naevus was present in 64%. PRAME immunohistochemistry showed negative or weakly patchy positive staining in all BIMT.ConclusionsBIMT are more common in a sporadic setting and behave indolently, despite worrying cytological atypia. PRAME immunohistochemistry is a reassuring tool in distinguishing BIMT from melanoma.","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"26 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2‐positive grade 1 invasive carcinomas of the breast HER2 阳性 1 级乳腺浸润癌

IF 6.4 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-11 DOI: 10.1111/his.15315

Andrew H S Lee, Zsolt Hodi, Areeg Abbas, Ian O Ellis, Emad A Rakha

AimsThe American Society of Clinical Oncology and College of American Pathologists HER2‐guidelines recommend repeat testing for most grade 1 mammary carcinomas that are HER2‐positive in the core biopsy. This study aimed to assess the value of repeat HER2‐testing and the histological features of HER2‐positive grade 1 carcinomas.Methods and resultsA case‐series of HER2‐results of grade 1 carcinomas was conducted of patients with no pre‐operative systemic treatment over a 5‐year period. HER2‐positive carcinomas had histological review. Twelve HER2‐positive carcinomas were initially reported as grade 1. On review, two were reclassified as grade 2. The remaining 10 carcinomas represented 2% of the 508 grade 1 carcinomas. Eight HER2‐positive grade 1 carcinomas from other years were also studied. HER2‐positive carcinomas more often had marked nuclear pleomorphism (50 versus 6%) and were more often oestrogen receptor‐negative (17 versus 0.8%) and progesterone receptor‐negative (28 versus 8%) compared with HER2‐negative grade 1 carcinomas. Six carcinomas that were HER2 3+ in the core biopsy were also 3+ on repeat assessment. Five of seven carcinomas that were 2+ amplified in the core biopsy were also HER2‐positive in the excision.ConclusionsHER2‐positive grade 1 carcinomas are uncommon, and more often have marked nuclear pleomorphism and lack oestrogen receptor and progesterone receptor expression compared with HER2‐negative grade 1 carcinomas. A HER2‐poitive result in the core biopsy was confirmed in 11 of 13 tumours that had repeat testing.

目的美国临床肿瘤学会和美国病理学家学会 HER2-指南建议对大多数核心活检呈 HER2 阳性的 1 级乳腺癌进行重复检测。本研究旨在评估重复 HER2 检测的价值以及 HER2 阳性 1 级癌的组织学特征。方法和结果对 5 年内术前未接受系统治疗的 1 级癌患者进行了 HER2 结果病例系列研究。对 HER2 阳性癌进行了组织学检查。12 例 HER2 阳性癌最初被报告为 1 级。经复查，其中两例被重新划分为 2 级。其余 10 例癌占 508 例 1 级癌的 2%。此外，还对其他年份的 8 例 HER2 阳性 1 级癌进行了研究。与HER2阴性1级癌相比，HER2阳性癌更常见于明显的核多形（50对6%），更常见于雌激素受体阴性（17对0.8%）和孕激素受体阴性（28对8%）。在核心活检中HER2为3+的6个癌瘤在再次评估时也是3+。结论HER2阳性的1级癌并不常见，与HER2阴性的1级癌相比，它们通常具有明显的核多形性，缺乏雌激素受体和孕激素受体表达。在重复检测的13个肿瘤中，有11个肿瘤的核心活检结果证实HER2阳性。

{"title":"HER2‐positive grade 1 invasive carcinomas of the breast","authors":"Andrew H S Lee, Zsolt Hodi, Areeg Abbas, Ian O Ellis, Emad A Rakha","doi":"10.1111/his.15315","DOIUrl":"https://doi.org/10.1111/his.15315","url":null,"abstract":"AimsThe American Society of Clinical Oncology and College of American Pathologists HER2‐guidelines recommend repeat testing for most grade 1 mammary carcinomas that are HER2‐positive in the core biopsy. This study aimed to assess the value of repeat HER2‐testing and the histological features of HER2‐positive grade 1 carcinomas.Methods and resultsA case‐series of HER2‐results of grade 1 carcinomas was conducted of patients with no pre‐operative systemic treatment over a 5‐year period. HER2‐positive carcinomas had histological review. Twelve HER2‐positive carcinomas were initially reported as grade 1. On review, two were reclassified as grade 2. The remaining 10 carcinomas represented 2% of the 508 grade 1 carcinomas. Eight HER2‐positive grade 1 carcinomas from other years were also studied. HER2‐positive carcinomas more often had marked nuclear pleomorphism (50 versus 6%) and were more often oestrogen receptor‐negative (17 versus 0.8%) and progesterone receptor‐negative (28 versus 8%) compared with HER2‐negative grade 1 carcinomas. Six carcinomas that were HER2 3+ in the core biopsy were also 3+ on repeat assessment. Five of seven carcinomas that were 2+ amplified in the core biopsy were also HER2‐positive in the excision.ConclusionsHER2‐positive grade 1 carcinomas are uncommon, and more often have marked nuclear pleomorphism and lack oestrogen receptor and progesterone receptor expression compared with HER2‐negative grade 1 carcinomas. A HER2‐poitive result in the core biopsy was confirmed in 11 of 13 tumours that had repeat testing.","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"9 1","pages":""},"PeriodicalIF":6.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142204081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proposal for a reappraisal of the current classification of so-called “somatic-type” malignancies arising in germ cell tumours 关于重新评估生殖细胞肿瘤中出现的所谓 "体细胞型 "恶性肿瘤的现行分类的建议

IF 3.9 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-10 DOI: 10.1111/his.15288

Andres M Acosta, Daniel M Berney, João Lobo, Muhammad T Idrees, Thomas M Ulbright

引用次数: 0

Myxoid “pauci‐hemosiderotic” fibrolipomatous tumour: a diagnostic challenge 肌样'贫血红蛋白'纤维脂肪瘤：诊断难题

IF 6.4 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-10 DOI: 10.1111/his.15317

Paige O'Connor, Julia A Bridge, Jeanne M Meis, Jeffrey M Cloutier

引用次数: 0

Histological sampling protocols for transurethral resection of prostate specimens need reappraisal 经尿道前列腺切除术标本的组织学取样方案需要重新评估

IF 3.9 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-10 DOI: 10.1111/his.15283

Murali Varma, Mahul B Amin, Daniel M Berney, Eva Compérat, Jonathan I Epstein, Kenneth A Iczkowski, Glen Kristiansen, Gladell P Paner, Rajal B Shah, Greg Shaw, Theodorus H van der Kwast, Geert J van Leenders, Ming Zhou, Sean R Williamson

引用次数: 0

SOX17 expression in mesonephric-like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Müllerian biomarker SOX17在女性生殖道间肾样腺癌和间肾残留/增生症中的表达：拓展其作为Müllerian生物标志物的用途。

IF 3.9 2区医学 Q2 CELL BIOLOGY

Histopathology

Pub Date : 2024-09-08 DOI: 10.1111/his.15308

Xiaoming Zhang, W. Glenn McCluggage, Brooke E Howitt, Michelle S Hirsch

Aims

Recently, SOX17 has emerged as a promising biomarker for non-mucinous Müllerian (ovarian and endometrial) carcinomas, demonstrating increased specificity in comparison to PAX8 while maintaining similar sensitivity. However, expression of SOX17 in mesonephric-like adenocarcinoma (MLA), a carcinoma of the female genital tract with uncertain, but probably Müllerian histogenesis, remains unexplored. This study aims to address this gap.

Methods and results

SOX17 immunohistochemistry was performed on whole tissue sections from 68 MLAs originating from the endometrium or ovary and seven cervical mesonephric carcinomas, as well as six mesonephric remnants/hyperplasias. Using a four-tiered scoring system based on distribution and intensity of staining, 68% of MLA displayed a negative/low (< 10%) SOX17 expression pattern, which contrasts with the high expression observed in most Müllerian carcinomas. However, 22% of MLA demonstrated high SOX17 expression, similar to other endometrial and ovarian carcinomas. Similarly, five of seven (72%) mesonephric carcinomas of the cervix were SOX17-negative, but two cases (28%) were positive. All mesonephric remnants/hyperplasias were SOX17 negative.

Conclusions

The majority of MLA are negative or exhibit low SOX17 expression, in contrast to the diffuse and strong expression commonly seen in other types of Müllerian carcinoma. However, a subset of MLAs demonstrate high SOX17 expression. Therefore, absence of SOX17 staining is supportive for MLA when the differential includes another non-mucinous Müllerian carcinoma. SOX17 may also be useful for differentiating mesonephric remnants/hyperplasias from Müllerian malignancies and benign Müllerian glandular lesions.

目的：最近，SOX17已成为非黏液性Müllerian（卵巢和子宫内膜）癌的一种有前途的生物标记物，与PAX8相比，SOX17的特异性更高，同时保持了相似的敏感性。然而，SOX17在间肾样腺癌（MLA）中的表达仍未得到探索，间肾样腺癌是一种女性生殖道癌症，其组织发生机制不确定，但很可能是缪勒组织发生。本研究旨在填补这一空白：对来自子宫内膜或卵巢的68例MLA、7例宫颈间质癌以及6例间质残留/增生的整个组织切片进行了SOX17免疫组化。根据染色的分布和强度采用四级评分法，68%的间叶癌呈阴性/低度染色（结论：大多数间叶癌呈阴性或低度染色）：大多数MLA的SOX17呈阴性或低表达，这与其他类型的Müllerian癌中常见的弥漫性强表达形成鲜明对比。然而，也有一部分MLA表现出高SOX17表达。因此，当鉴别对象包括其他非黏液性穆勒氏癌时，SOX17染色缺失可支持穆勒氏癌。SOX17还可用于区分肾间质残余/增生症与Müllerian恶性肿瘤和良性Müllerian腺体病变。

{"title":"SOX17 expression in mesonephric-like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Müllerian biomarker","authors":"Xiaoming Zhang, W. Glenn McCluggage, Brooke E Howitt, Michelle S Hirsch","doi":"10.1111/his.15308","DOIUrl":"10.1111/his.15308","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Recently, SOX17 has emerged as a promising biomarker for non-mucinous Müllerian (ovarian and endometrial) carcinomas, demonstrating increased specificity in comparison to PAX8 while maintaining similar sensitivity. However, expression of SOX17 in mesonephric-like adenocarcinoma (MLA), a carcinoma of the female genital tract with uncertain, but probably Müllerian histogenesis, remains unexplored. This study aims to address this gap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>SOX17 immunohistochemistry was performed on whole tissue sections from 68 MLAs originating from the endometrium or ovary and seven cervical mesonephric carcinomas, as well as six mesonephric remnants/hyperplasias. Using a four-tiered scoring system based on distribution and intensity of staining, 68% of MLA displayed a negative/low (< 10%) SOX17 expression pattern, which contrasts with the high expression observed in most Müllerian carcinomas. However, 22% of MLA demonstrated high SOX17 expression, similar to other endometrial and ovarian carcinomas. Similarly, five of seven (72%) mesonephric carcinomas of the cervix were SOX17-negative, but two cases (28%) were positive. All mesonephric remnants/hyperplasias were SOX17 negative.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The majority of MLA are negative or exhibit low SOX17 expression, in contrast to the diffuse and strong expression commonly seen in other types of Müllerian carcinoma. However, a subset of MLAs demonstrate high SOX17 expression. Therefore, absence of SOX17 staining is supportive for MLA when the differential includes another non-mucinous Müllerian carcinoma. SOX17 may also be useful for differentiating mesonephric remnants/hyperplasias from Müllerian malignancies and benign Müllerian glandular lesions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 5","pages":"820-825"},"PeriodicalIF":3.9,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Histopathology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀